NO147750C - Analogifremgangsmaate for fremstilling av terapeutisk aktive og optisk aktive 11-desoksy-16-aryloksy-omega-tetranorprostaglandiner - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive og optisk aktive 11-desoksy-16-aryloksy-omega-tetranorprostaglandiner

Info

Publication number
NO147750C
NO147750C NO762154A NO762154A NO147750C NO 147750 C NO147750 C NO 147750C NO 762154 A NO762154 A NO 762154A NO 762154 A NO762154 A NO 762154A NO 147750 C NO147750 C NO 147750C
Authority
NO
Norway
Prior art keywords
active
tetranorprostaglandines
desoxy
omega
aryloxy
Prior art date
Application number
NO762154A
Other languages
English (en)
Norwegian (no)
Other versions
NO147750B (no
NO762154L (cs
Inventor
Jasjit Singh Bindra
Thomas Ken Shcaaf
James Frederick Eggler
Michael Ross Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO762154L publication Critical patent/NO762154L/no
Publication of NO147750B publication Critical patent/NO147750B/no
Publication of NO147750C publication Critical patent/NO147750C/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO762154A 1975-06-23 1976-06-22 Analogifremgangsmaate for fremstilling av terapeutisk aktive og optisk aktive 11-desoksy-16-aryloksy-omega-tetranorprostaglandiner NO147750C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58938675A 1975-06-23 1975-06-23

Publications (3)

Publication Number Publication Date
NO762154L NO762154L (cs) 1976-12-27
NO147750B NO147750B (no) 1983-02-28
NO147750C true NO147750C (no) 1983-06-08

Family

ID=24357789

Family Applications (1)

Application Number Title Priority Date Filing Date
NO762154A NO147750C (no) 1975-06-23 1976-06-22 Analogifremgangsmaate for fremstilling av terapeutisk aktive og optisk aktive 11-desoksy-16-aryloksy-omega-tetranorprostaglandiner

Country Status (31)

Country Link
US (1) US4157341A (cs)
JP (2) JPS523040A (cs)
AR (1) AR218224A1 (cs)
AT (1) AT361140B (cs)
BE (1) BE843236A (cs)
BG (1) BG27355A3 (cs)
CH (1) CH619691A5 (cs)
CS (1) CS191310B2 (cs)
DD (1) DD130036A5 (cs)
DE (1) DE2626888C2 (cs)
DK (1) DK273376A (cs)
EG (1) EG12413A (cs)
ES (1) ES449096A1 (cs)
FI (1) FI761810A (cs)
FR (1) FR2316924A1 (cs)
GB (1) GB1557482A (cs)
GR (1) GR60047B (cs)
HU (1) HU179275B (cs)
IE (1) IE43462B1 (cs)
IL (1) IL49788A0 (cs)
IN (1) IN145123B (cs)
LU (1) LU75224A1 (cs)
NL (1) NL7606825A (cs)
NO (1) NO147750C (cs)
NZ (1) NZ181150A (cs)
PL (1) PL117820B1 (cs)
PT (1) PT65255B (cs)
SE (2) SE7605959L (cs)
SU (1) SU679134A3 (cs)
YU (1) YU147976A (cs)
ZA (1) ZA763689B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2629834A1 (de) * 1976-06-30 1978-01-12 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
DK523378A (da) * 1978-01-16 1979-07-17 Pfizer Fremgangsmaade til fremstilling af n-(tetrazol-5-yl) prostaglandin-carboxamider eller salte deraf
US4455421A (en) * 1979-02-22 1984-06-19 Pfizer Inc. 11-Desoxy-16-aryloxy-ω-tetranorprostaglandins
DE2967236D1 (de) * 1979-07-17 1984-10-31 Pfizer N-alkanesulfonyl 16,16-dimethyl-17-oxaprostaglandin carboxamides
JPS5930963A (ja) * 1982-08-16 1984-02-18 センカ株式会社 殺菌性繊維
JPS60122444U (ja) * 1984-01-30 1985-08-17 トステム株式会社 サイデイングの施工構造
JPS61274043A (ja) * 1985-05-28 1986-12-04 元旦ビユーティ工業株式会社 外装壁の補修方法
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
JPH0573141U (ja) * 1992-03-09 1993-10-05 株式会社チューオー 改修工事における外壁下地部材
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7183310B2 (en) 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO2007056087A1 (en) 2005-11-03 2007-05-18 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2508995A1 (de) * 1975-03-01 1976-09-09 Merck Patent Gmbh Prostansaeurederivate

Also Published As

Publication number Publication date
PL117820B1 (en) 1981-08-31
NZ181150A (en) 1978-07-28
NL7606825A (nl) 1976-12-27
AU1510976A (en) 1978-01-05
AR218224A1 (es) 1980-05-30
EG12413A (en) 1979-03-31
IE43462L (en) 1976-12-23
DD130036A5 (de) 1978-03-01
ES449096A1 (es) 1977-07-01
DK273376A (da) 1976-12-24
FI761810A (cs) 1976-12-24
JPS5754506B2 (cs) 1982-11-18
ATA457076A (de) 1980-07-15
PT65255B (en) 1977-12-06
IL49788A0 (en) 1976-08-31
SE7605959L (sv) 1976-12-24
BE843236A (fr) 1976-12-22
DE2626888A1 (de) 1977-04-07
NO147750B (no) 1983-02-28
YU147976A (en) 1982-06-30
US4157341A (en) 1979-06-05
SE8100410L (sv) 1981-01-23
IE43462B1 (en) 1981-03-11
FR2316924A1 (fr) 1977-02-04
LU75224A1 (cs) 1977-03-15
HU179275B (en) 1982-09-28
DE2626888C2 (de) 1982-05-06
CH619691A5 (cs) 1980-10-15
JPS5829759A (ja) 1983-02-22
FR2316924B1 (cs) 1981-03-06
IN145123B (cs) 1978-08-26
GB1557482A (en) 1979-12-12
GR60047B (en) 1978-04-01
BG27355A3 (en) 1979-10-12
PT65255A (en) 1976-07-01
ZA763689B (en) 1978-02-22
CS191310B2 (en) 1979-06-29
JPS523040A (en) 1977-01-11
SU679134A3 (ru) 1979-08-05
NO762154L (cs) 1976-12-27
AT361140B (de) 1981-02-25

Similar Documents

Publication Publication Date Title
NO147243C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater
NO149586C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive polypeptider
NO147450C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolonderivater
NO143219C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO151411C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-aryloksy-2-hydroksy-3-alkylenaminopropan-derivater
NO151040C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-halogenpyrimid-2-oner
NO800881L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater
NO144848C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 4-hydroksyfenylalkanolamin-derivater
NO148777C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antrakinon-derivater
NO146865C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 16-dehydro-androstanderivater
NO150044C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrazol-derivater
NO147750C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive og optisk aktive 11-desoksy-16-aryloksy-omega-tetranorprostaglandiner
NO146359C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive cyproheptadinderivater
NO149313C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO151239C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenyliminoimidazolidiner
NO149037C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO145163C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive antitumorglykosider
NO148488C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive acyl-benzimidazol-2-derivater
NO802277L (no) Fremgangsmaate til fremstilling av terapeutisk aktive 25-halocholest-5-en-3beta,22-dioler og estere derav
NO143903C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-fluorpyrimidin-4-on-derivater
NO794318L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spiro-kinolyl-hydantoin-derivater
NO144741C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiopyrano-pyrazoler
NO152556C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antracen-biskarbonylhydrazoner
NO144019C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive naftyridinderivater
NO146061C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive derivater av 2-iminothiazolidiner og 2-iminothiazoliner